NCT01203384View on ClinicalTrials.gov

Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Alzheimer's Disease
Interventions
DRUG

CHF5074 1x

oral tablet, 1x, once a day in the morning for 14 days

DRUG

CHF5074 2x

oral tablet, 2x, once a day in the morning for 14 days

DRUG

CHF5074 3x

oral tablet, 3x, once a day in the morning for 14 days

DRUG

Placebo

oral tablet, placebo, once a day in the morning for 14 days

Trial Locations (1)

07724

Iberica Clinical Research Center, Eatontown

Sponsors

Lead Sponsor

CERESPIR
All Listed Sponsors
lead

CERESPIR

INDUSTRY